Gosset Ownership
Private
Employees
~11
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Photys Therapeutics General Information
Photys has presented preclinical data on its bifunctional molecules driving apoptosis in cancer models and has licensed a Phase I-ready IRAK4 degrader. No clinical results have been published yet; programs are primarily in preclinical or IND-enabling stages.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Cambridge, Massachusetts
United States
United States
Drug Pipeline
Phase 1
Key Partnerships
Novo Nordisk – research collaboration for cardiometabolic disease using PHICS technology, Polymed – exclusive license agreement for Phase I-ready IRAK4 degrader
Photys Therapeutics Funding
No funding data available
To view Photys Therapeutics's complete valuation and funding history, request access »